Heptares selected muscarinic receptors as one of the first GPCR ... This resource, combined with its improving structure-based drug design platform, is helping partners at earlier stages of ...

The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...

A Vanderbilt University patent discloses new muscarinic M4 receptor positive allosteric modulators and agonists reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Nxera and Neurocrine entered a collaboration and licensing agreement in 2021 to develop a portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual M1/M4 receptor ...

These compounds are: NBI-1117570 (a dual M1 / M4 agonist) NBI-1117567 (an M1-preferring agonist) NBI-1117569 (an M4-preferring agonist) Nxera and Neurocrine entered a collaboration and licensing ...

These compounds are: NBI-1117570 (a dual M1 / M4 agonist) NBI-1117567 (an M1-preferring agonist) NBI-1117569 (an M4-preferring agonist) Nxera and Neurocrine entered a collaboration and licensing ...